NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Biond Biologics

Biond Biologics

Private
IsraelHealthcare & Life Scienceshttps://www.biondbio.com/

Last Round

Strategic

Jun 1, 2026

Total Funding Raised

$40M

Company Overview

Biond Biologics is a biotechnology company that develops first-in-class immunotherapies for the treatment of cancer and immune-mediated diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

cancer immunotherapyimmuno-oncologyantibody therapyimmune checkpoint inhibitorILT2 inhibitorfirst-in-class therapyclinical-stage biotechmonoclonal antibodyintracellular deliverydrug delivery platformpharma licensingILT3 inhibitorsolid tumor therapyinnate immunityNSCLCCRC

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Biond Biologics Comparables

Compare Biond Biologics with similar companies based on industry and business-model similarity.

Biond Biologics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tizona Therapeutics
80%
Compugen Ltd.
79%
Invectys
78%

Biond Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicJun 1, 2026
Series CNov 3, 2021
Series BJan 8, 2019

Key People

Founding team and executive leadership

Tehila Ben-Moshe

Chief Executive Officer

Executive Team

Avidor Shulman

CTO

Executive Team

Biond Biologics Investors

Notable investors and investment history

Biond Biologics investors
InvestorRounds
Israel Biotech FundSeries B
Deep InsightSeries C
The Heritage GroupSeries C
SBI JISeries B
Harel Insurance Investments & Financial ServicesSeries C, Series B

Biond Biologics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Biond Biologics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Biond Biologics's valuation, stock price, and market status.

Firmographic Details

HeadquartersIsrael
Employee Range35
Year Founded2016
Last FundingJun 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.